GenMark Diagnostics Reports Fourth Quarter and Full Year 2019 Results
CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced
financial results for the fourth quarter and year ended December 31, 2019.
Full Year 2019 Financial Highlights
- Total revenue of $88.0 million, an increase of 24% over 2018
-- ePlex revenue of $60.3 million, an increase of more than 59% over 2018
- Gross margin of 32.5%, a 500-bps improvement over 2018
- Ended the year with $53.5 million in cash and investments
Fourth Quarter 2019 Financial Highlights
- Total revenue of $27.2 million, an increase of 40% over the fourth quarter of 2018
-- ePlex revenue of $19.2 million, an increase of approximately 58% over the fourth quarter of 2018
- Gross margin of 33.5%, a 630-bps improvement over the fourth quarter of 2018
Recent Operational Highlights
- Placed 38 net new ePlex analyzers in the fourth quarter of 2019, expanding the global installed base to 527 at year end
- Approximate average annuity per ePlex analyzer of $148,000, compared to $139,000 in the comparable period of 2018
- Over 70% of placements in the fourth quarter were within labs that previously had a competitive analyzer
- Shipped initial Research Use Only (RUO) test kits designed to detect the SARS-CoV-2 virus to several key sites in the U.S. with access to clinical samples and to the company’s Hong Kong distributor
“2019 was a turning point for our company. From the FDA clearance and launch of our suite of blood culture identification panels to our significant improvement in gross margin, our team delivered meaningful results through teamwork and clearly defined goals,” said Scott Mendel, Interim President and Chief Executive Officer. “I am confident that we will build on these achievements and drive strong revenue growth and improving margins in 2020.”
“As revenue crosses over the $100 million mark in 2020, we are increasingly focused on driving towards cash flow positivity. We expect continued strong U.S. ePlex revenue growth, which is the vast majority of our business. Internationally, we plan to take a more measured approach that balances additional placements with stronger leverage of 2019’s geographic expansion,” concluded Mendel.
Fourth Quarter Financial Results
Revenue was $27.2 million in the fourth quarter of 2019, an increase of 40% versus $19.4 million in the fourth quarter of 2018.
Gross profit was $9.1 million, or approximately 33.5% of revenue, compared with $5.3 million, or 27.2% of revenue in the same period of 2018.
Operating expenses for the fourth quarter of 2019 were $17.8 million compared to $15.9 million in the same period of 2018. The increase was largely due to higher BCID launch and ePlex development expenses.
Loss per share was $0.17 for the fourth quarter of 2019, compared to a $0.21 loss per share in the fourth quarter of 2018.
Full Year 2019 Financial Results
Revenue was $88.0 million in 2019, an increase of 24% versus $70.8 million in 2018. Gross profit was $28.6 million, or 32.5% of revenue, compared with $19.5 million, or 27.5% of revenue in the prior year.
Operating expenses for 2019 were $70.4 million compared to $67.3 million in 2018. The increase was largely due to higher BCID launch and ePlex development expenses.
Loss per share was $0.82 for 2019, compared to a $0.91 loss per share in 2018.
Cash and investments were $53.5 million as of December 31, 2019.
Guidance for Full Year 2020
The company expects revenue for the full year 2020 in the range of $100 million to $110 million, which represents growth of 14% to 25%, updated from 20-25% previously communicated. ePlex revenues are expected to increase by more than 30% in 2020 and represent approximately 70% to 80% of total 2020 revenue.
Global ePlex placements are expected to range from 130 to 160 net new analyzers with an annuity per analyzer between $130,000 and $135,000.
Gross margin is expected to be in the 36% to 39% range and operating expenses are expected to be approximately $65 million to $70 million.
Cash used in operations is projected to decline year over year to between $16 million and $20 million.
Webcast and Conference Call Information
GenMark will host a conference call to discuss fourth quarter results in further detail on Monday, March 2, 2020 starting at 4:30 p.m. ET. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 8163576 approximately five minutes prior to the start time.
About GenMark Diagnostics
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor detection technology, GenMark's eSensor XT-8 and ePlex systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Safe Harbor Statement
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our future financial performance, regulatory submissions and approvals, plans and objectives of management, and the timely and effective commercialization and clinical impact of our ePlex system, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to successfully commercialize our ePlex system and its related test menu in a timely manner, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, our ability to successfully expand sales of our product offerings outside the United States, and third-party payor reimbursement to our customers, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
|As of December 31,|
|Cash and cash equivalents||$||44,360||$||36,286|
|Short-term marketable securities||9,100||8,882|
|Accounts receivable, net of allowances of $376 and $75, respectively||16,759||11,534|
|Prepaid expenses and other current assets||1,877||1,483|
|Total current assets||83,397||68,429|
|Property and equipment, net||20,419||21,070|
|Intangible assets, net||1,432||2,023|
|Noncurrent operating lease right-of-use assets||4,642||—|
|Other long-term assets||825||701|
|LIABILITIES AND STOCKHOLDERS' EQUITY:|
|Current operating lease liability||1,842||—|
|Other current liabilities||2,732||3,043|
|Total current liabilities||24,316||20,287|
|Noncurrent operating lease liability||5,796||—|
|Other noncurrent liabilities||53||109|
|Commitments and contingencies - See Note 7|
|Preferred stock, $0.0001 par value; 5,000 authorized, none issued||—||—|
|Common stock, $0.0001 par value; 100,000 authorized; 60,255 and 56,240 shares issued and outstanding as of December 31, 2019 and 2018, respectively||6||6|
|Additional paid-in capital||526,294||500,344|
|Accumulated other comprehensive income||96||80|
|Total stockholders’ equity||12,163||33,547|
|Total liabilities and stockholders’ equity||$||111,473||$||92,981|
GENMARK DIAGNOSTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share data)
|Three Months Ended||Twelve Months Ended|
|December 31,||December 31,|
|License and other revenue||118||53||530||278|
|Cost of revenue||18,079||14,106||59,418||51,278|
|Sales and marketing||6,127||5,813||24,118||21,777|
|General and administrative||4,942||4,147||19,159||17,545|
|Research and development||6,754||5,924||27,140||27,931|
|Total operating expenses||17,823||15,884||70,417||67,253|
|Loss from operations||(8,706||)||(10,612||)||(41,814||)||(47,772||)|
|Other income (expense):|
|Other (expense) income||11||(143||)||(23||)||(192||)|
|Total other expense||(1,545||)||(871||)||(5,472||)||(2,589||)|
|Loss before provision for income taxes||(10,251||)||(11,483||)||(47,286||)||(50,361||)|
|Income tax expense||36||80||64||139|
|Net loss per share, basic and diluted||$||(0.17||)||$||(0.21||)||$||(0.82||)||$||(0.91||)|
|Weighted average number of shares outstanding, basic and diluted||58,915||56,065||57,603||55,669|
|Other comprehensive loss:|
|Other comprehensive income (loss):|
|Foreign currency translation adjustments, net of tax||48||15||11||44|
|Net unrealized gains (losses) on marketable securities, net of tax||(3||)||1||5||27|
|Total other comprehensive income (loss)||45||16||16||71|
|Total comprehensive loss||$||(10,242||)||$||(11,547||)||$||(47,334||)||$||(50,429||)|
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
|Years ended December 31,|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||7,268||7,088||5,317|
|Net accretion of premiums/discounts on investments||(133||)||(142||)||(39||)|
|Amortization of deferred debt issuance costs||1,740||938||1,132|
|Provision for bad debt||338||23||14|
|Non-cash inventory adjustments||2,631||1,426||1,323|
|Other non-cash adjustments||537||15||(224||)|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||(750||)||854||(599||)|
|Other current and non-current liabilities||249||(289||)||(893||)|
|Net cash used in operating activities||(34,926||)||(32,512||)||(53,422||)|
|Payments for intellectual property licenses||—||—||(500||)|
|Purchases of property and equipment||(2,092||)||(2,575||)||(4,815||)|
|Purchases of marketable securities||(32,135||)||(29,778||)||(70,989||)|
|Proceeds from sales of marketable securities||—||—||13,896|
|Maturities of marketable securities||32,055||66,300||37,500|
|Net cash (used in) provided by investing activities||(2,172||)||33,947||(24,908||)|
|Proceeds from issuance of common stock||14,021||1,061||87,267|
|Costs incurred in conjunction with public offering||(574||)||—||(5,469||)|
|Principal repayment of borrowings||(35,093||)||(92||)||(7,848||)|
|Proceeds from borrowings||70,000||7,098||15,000|
|Costs associated with debt issuance||(3,638||)||(20||)||(187||)|
|Proceeds from stock option exercises||457||22||287|
|Net cash provided by financing activities||45,173||8,069||89,050|
|Effect of exchange rate changes on cash||(1||)||28||75|
|Net increase in cash and cash equivalents||8,074||9,532||10,795|
|Cash and cash equivalents at beginning of year||37,044||27,512||16,717|
|Cash and cash equivalents at end of year||$||45,118||$||37,044||$||27,512|
|Non-cash investing and financing activities:|
|Transfer of systems from inventory to property and equipment||$||2,846||$||1,689||$||4,885|
|Property and equipment costs incurred but not paid included in accounts payable||$||1,234||$||372||$||227|
|Supplemental cash flow information:|
|Cash paid for interest||$||3,946||$||2,028||$||1,643|
|Cash paid for income taxes, net||$||155||$||165||$||61|